WO2006063526A1 - Utilisation de la cymipristone pour le traitement de la depression - Google Patents
Utilisation de la cymipristone pour le traitement de la depression Download PDFInfo
- Publication number
- WO2006063526A1 WO2006063526A1 PCT/CN2005/002194 CN2005002194W WO2006063526A1 WO 2006063526 A1 WO2006063526 A1 WO 2006063526A1 CN 2005002194 W CN2005002194 W CN 2005002194W WO 2006063526 A1 WO2006063526 A1 WO 2006063526A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- depression
- group
- hydrogen
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to the field of medicinal chemistry, and in particular, to the use of cymesone compounds for the preparation of a medicament for the treatment of depression.
- depression Due to the rapid development of the modern economy and the significant increase in social pressure, the incidence of depression has increased year by year. In the past 10 years, depression has become one of the most common public health diseases in the world. People suffer from depression in their lifetime. The probability is 10% - 25%, the most serious consequence of which is suicide, more than 1 million people each year. According to figures published by the World Psychiatric Association, global depression patients are increasing year by year with a growth rate of 113%. Depression has become a "episode in the 21st century.”
- Depression is also known as Depressive Disorder.
- the main clinical features are significant and persistent depression. It is characterized by decreased energy, persistent fatigue, decreased activity and loss of interest. (Key to the diagnosis and treatment of depression), Zhu Ziqing Et al., 2003 edition, P1).
- the classification of depression can be divided according to the severity of the disease.
- ICD-10 International Classification of Diseases System, 10th edition (ICD-10, 1992), prepared by the World Health Organization, depressive episodes are classified as mild, moderate, and severe, based on the number, type, subjective experience, and society of symptoms.
- the severity of functional involvement Key to the diagnosis and treatment of depression disorders, Zhu Ziqing, etc.
- Major depressive also known as Major depressive disorder refers to one or more severe (severe) depressive episodes without manic episodes, hypomanic episodes or mixed Episodes of Depression (Diagnosis and Treatment of Depressive Disorders, edited by Yang Quan, 2003 edition, P152).
- Psychot ic major depression also known as Psychot ic depres s ion
- cortisol Human cortisone (cortisol) is secreted by corticosteroids such as dexamethasone
- the dexamethasone suppression test is a sensitive indicator of the feedback inhibition of exogenous cortisol on the HPA axis. If dexamethasone does not inhibit cortisol secretion (positive DST test), the HPA axis is overactive, the DST positive rate of patients with depression is about 40-50%, and the false positive rate of normal DST is only 4%. - 10% (Wang Xueming et al., Biochemistry of Mental and Psychiatric Diseases, 2000, P368), which indicates that many patients with depression suffer from a decrease in the feedback function of the HPA axis, resulting in a sustained increase in cortisol secretion.
- DST dexamethasone suppression test
- a sustained increase in the concentration of cortisol (glucocorticoid) in the human body produces a range of biological effects. Its effects on neurotransmitters include: 1 reducing serotonin energy; 2 reducing norepinephrine; 3 increasing dopamine (DA) energy.
- the effects on endocrine include: 1 increasing the secretion of adrenocorticotropic hormone (CRH); 2 inhibiting the hypothalamic-pituitary-thyroid axis; 3 inhibiting the hypothalamic-pituitary-gonadal axis; 4 increasing the secretion of growth hormone (GH); 5 raise blood sugar.
- CCH adrenocorticotropic hormone
- GH growth hormone
- the above series of changes are an important cause of depression (Yu Dongshan. National Journal of Behavioral Medical Sciences, 2000, V9 (4), P317).
- Mifepristone (RU 486) is a glucocorticoid receptor antagonist developed by Russell-Ukraf, France. It has a high affinity with the glucocorticoid receptor and is resistant to glucocorticoid action ( 3 The effect of H-TdR incorporation into rat thymocyte DNA cultured in vitro and mouse thymic degeneration test showed that mifepristone has anti-glucocorticoid activity, indicating that it is a receptor-level glucocorticoid antagonist. In 1993, Murphy et al. succeeded in exploratory clinical trials of mifepristone in the treatment of major depression (Journal of Psychiatry Neuroscience, 1993, V18: P209).
- glucocorticoid receptor antagonists such as mifepristone and other effective mechanisms for the treatment of depression are mainly: (1) Compensatory increase in the number of glucocorticoid receptors due to anti-glucose glucosamine activity, resulting in Increased negative feedback to the HPA axis and restores its function to normal; (2) Glucocorticoid receptor antagonists block the action of glucocorticoid receptors, thereby blocking the increase in circulating cortisol levels Harmful effects. (McQUADE & YOUNG. British Journal of Psychiatry, 2000, Vol 177: P390).
- the cymesone compound according to the present invention is a steroid compound of the following formula or a pharmaceutically acceptable salt or isomer thereof:
- cymesone is a novel glucocorticoid receptor antagonist.
- Pharmacological tests have shown that sirmizone has the same anti-glucocorticoid activity as mifepristone; cymesones have a strong affinity with glucocorticoid receptors, and this affinity exceeds mifepristone Affinity with the glucocorticoid receptor.
- the above test demonstrates that cymesone is a receptor-level glucocorticoid antagonist that blocks glucocorticoid receptor action and can be used to repair glucocorticoid receptor-mediated HPA axis negative feedback regulation mechanisms. Thereby treating depression, especially major depression, especially psychotic major depression. The present invention has thus been completed.
- the present invention provides the use of a cymesone compound for the preparation of a medicament for the treatment of depression.
- the invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or isomer thereof, for use in the treatment of depression, particularly major depression, particularly psychotic major depression.
- cymesone compounds can be used for the treatment of depression, especially major depression, especially psychotic major depression.
- the cymesone compound according to the present invention is a known bulk compound having the following general formula (I):
- the compound of the present invention may exist in the form of a pharmaceutically acceptable salt, and since it has a plurality of asymmetric carbon atoms therein, the compound may have a plurality of isomers, and these salts and isomers are all claimed for the use of the compound of the present invention. Scope of use.
- the compound of the formula (I) of the present invention is preferably a compound wherein R 2 is hydrogen or a fluorenyl group, and R 3 is a fluorenyl group or a hydroxymethyl group, or a pharmaceutically acceptable salt or isomer thereof.
- More preferred compounds of the invention include:
- simipirone compounds similar to mifepristone compounds, are glucocorticoid receptor antagonists that block the action of glucocorticoid receptors and can be used for therapeutic treatment.
- Glucocorticoid receptor-mediated disorders caused by sinusoidal negative feedback regulation mechanisms can be used to treat depression, particularly major depression, especially psychotic major depression.
- a pharmaceutical composition for treating depression particularly major depression, especially psychotic major depression, which may be in the form of a tablet or a capsule.
- the form of a solid preparation such as a pill, a granule, or the like may be in the form of a liquid preparation such as an injection, a suspension, an emulsion or a solution, or may be in the form of various transdermal preparations, and may also include a corresponding slow-acting preparation.
- Formulations with special effects such as release, controlled release, targeting, and pulse.
- Figure 1 shows cymes ketone, mifepristone against 3 H-DEX and rat liver cytoplasmic glucocorticoid receptor A competitive inhibition curve for specific binding.
- Example 1 Detection of cytosolic glucocorticoid receptor binding ability in rat liver serotonin (1) Test method
- mice Female clean SD rats, weighing 200-250 g, were dosed and given free access to water. The feeding temperature is controlled at around 24 degrees Celsius, and the illumination is 11 hours a day and 13 hours a day. All experimental animals were observed for 1 week before the experiment.
- the bilateral adrenal glands were removed from the lateral rib arch of the rat, and the bilateral adrenal glands were removed.
- the physiological saline was maintained to maintain the water-electrolyte balance.
- the animals were sacrificed three days after the operation, and the liver was quickly taken out in a water-cooled buffer to wash the blood as much as possible. A certain amount of tissue was added to the buffer at a ratio of 1:4, and the tissue was cut, and the tissue was homogenized at a low temperature, and centrifuged at 175,000 g for 1 hour, and the supernatant was taken for use.
- the protein concentration in the supernatant was measured and the concentration of the protein was adjusted to 2 mg/ml.
- the labeled, non-labeled dexamethasone (DEX), cymesone, and mifepristone dissolved in ethanol were evaporated at 37 ° C, and then competitive inhibition experiments were performed.
- Relative binding affinity Calculate the formula by using dexamethasone RBA equal to 100%.
- Test compound ic 50 ( nmol/L ) RBA ( )
- the RBA ratio of dexamethasone, cymesone and mifepristone was 1:5.6: 3.4, IC 5 . They were 14.50, 2.60, 4.21 nmol/L, IC 5 of sirpristone and mifepristone.
- the ratio of 1.00: 1.62 indicates that dexamethasone glucocorticoid receptor binding is stronger than mifepristone, which can block glucocorticoid receptor more effectively than mifepristone, and has a stronger treatment for depression. potential.
- mice Female clean SD rats, weighing 200 ⁇ 250 grams, were dosed and given free access to water. The feeding temperature is controlled at around 24 degrees Celsius, and the illumination is 11 hours in the day and 13 hours in the night. All experimental animals were observed for 1 week before the experiment.
- the rats were anesthetized with ether, and the bilateral incision was made under the dorsal rib arch of the mouse.
- the adrenal gland was completely removed and the saline was administered after operation.
- Animals were sacrificed on day 7 and the thymus was taken in HBSS buffer, washed twice, and the connective tissue was removed, then cut, gently ground with a slurry, filtered through three layers of gauze, and centrifuged for 5 minutes at low speed ( At 500 rpm, the pellet was washed twice with HBSS, and the cells were resuspended in RPMI1640 medium for cell count and cell viability, and the cell concentration was adjusted to 10 7 /ml.
- the test compound is added to the culture solution to a concentration of 6 x lO- s ⁇ 2 x lO- 6 mol/L, and the 37 C incubator is preset for 3 hours, and then thymocytes are added.
- the cell concentration was 107 ml, pre-incubated at 37 °C for 3 hours, and the mixture was incubated with the ⁇ mark for 1 hour, and the reaction was terminated by adding 5% trichloroacetic acid ⁇ ⁇ with water cooling.
- test tube was placed on ice, and then washed twice with water-cooled 2 ml of 5% trichloroacetic acid, centrifuged at 500 rpm for 5 minutes, and the cells were added with 0.5 ml of IN NaOH, the cells were lysed, and the solution was aspirated, and the residue was rubbed with a cotton swab. Dry, placed in the same scintillation bottle, liquid scintillation to determine radioactivity.
- the test selected concentrations of dexamethasone 610-8 detect anti-glucocorticoid activity, concentration of test compound of a 6 X 10 8 ⁇ 2 X 10-W / L.
- the spiroxol antiglucocorticoid activity was calculated according to the formula, including H 3 -TdR incorporation rate and residual inhibition rate. Wherein the concentration of dexamethasone 6 ⁇ 10- 8, the residual rate is calculated as 100% inhibition.
- Example 3 Preparation of a pharmaceutical composition preparation (tablet)
- Tablet prescription 200 grams of samidone, 10 grams of pregelatinized starch, 20 grams of dextrin, 10 grams of calcium sulfate, 10 grams of microcrystalline cellulose, 14 grams of crosslinked PVP, 2.5 grams of hypromellose, hard 3 grams of magnesium citrate (made in 1000 tablets).
- capsules 200 grams of samidone, 20 grams of corn starch, 20 grams of microcrystalline cellulose, 2.5 grams of hypromellose, and 3 grams of magnesium stearate (made of 1000 capsules).
- each capsule contains 200 grams of cymes.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410093036A CN100588393C (zh) | 2004-12-15 | 2004-12-15 | 赛米司酮类用于治疗抑郁症的用途 |
CN200410093036.5 | 2004-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006063526A1 true WO2006063526A1 (fr) | 2006-06-22 |
Family
ID=36587541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2005/002194 WO2006063526A1 (fr) | 2004-12-15 | 2005-12-15 | Utilisation de la cymipristone pour le traitement de la depression |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100588393C (zh) |
WO (1) | WO2006063526A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110590B (zh) * | 2009-12-29 | 2015-07-01 | 上海中西制药有限公司 | 赛米司酮固体制剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1287123A (zh) * | 1999-09-02 | 2001-03-14 | 上海中西药业股份有限公司 | 甾体化合物,其制备方法和其药物组合物及其应用 |
CN1528315A (zh) * | 1997-10-06 | 2004-09-15 | ������˹̹�������ѧ�й�ίԱ�� | 治疗糖皮质素功能失调相关性精神病的方法 |
-
2004
- 2004-12-15 CN CN200410093036A patent/CN100588393C/zh active Active
-
2005
- 2005-12-15 WO PCT/CN2005/002194 patent/WO2006063526A1/zh not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1528315A (zh) * | 1997-10-06 | 2004-09-15 | ������˹̹�������ѧ�й�ίԱ�� | 治疗糖皮质素功能失调相关性精神病的方法 |
CN1287123A (zh) * | 1999-09-02 | 2001-03-14 | 上海中西药业股份有限公司 | 甾体化合物,其制备方法和其药物组合物及其应用 |
Non-Patent Citations (1)
Title |
---|
BELANAOFF E TAL: "Rapid Reversal of Psychotic Depression Using Mifepristone.", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY., vol. 21, no. 5, 2001, pages 516, XP008172779 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103110590B (zh) * | 2009-12-29 | 2015-07-01 | 上海中西制药有限公司 | 赛米司酮固体制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100588393C (zh) | 2010-02-10 |
CN1788720A (zh) | 2006-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10231976B2 (en) | Methods for the use of progestogen as a glucocorticoid sensitizer | |
CN103582484B (zh) | 17-己酸羟孕酮(17-hpc)的肺部递送 | |
JP5969255B2 (ja) | 炎症関連疾患の治療法 | |
JP2013518908A5 (zh) | ||
CN104257657A (zh) | 用于治疗cmt和相关疾病的新治疗方法 | |
TW201002330A (en) | Compositions and methods for treating breast cancer | |
US20190269663A1 (en) | Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer | |
WO2007143930A1 (fr) | Utilisation de 20(s)-protopanoxadiol dans la fabrication d'antidépresseurs | |
Ahlenius et al. | Failure to antagonize the 8-hydroxy-2-(Dl-n-propylamino) tetralin-induced facilitation of male rat sexual behavior by the administration of 5-HT receptor antagonists | |
Lee et al. | Anti-inflammatory effects of ursolic acid-3-acetate on human synovial fibroblasts and a murine model of rheumatoid arthritis | |
KR20090067198A (ko) | 자궁내막 증식을 억제하는 조성물과 방법 | |
US20140329782A1 (en) | Combined therapeutic agent | |
TW200902027A (en) | Compositions and methods for treating medical conditions | |
US20080299207A1 (en) | Methods and compositions for administration of oxybutynin | |
Balzano et al. | Leukotriene receptor antagonists in the treatment of asthma: an update | |
US20080262071A1 (en) | Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder | |
WO2019106604A1 (en) | Pharmaceutical combination comprising lsz102 and alpelisib | |
WO2006063526A1 (fr) | Utilisation de la cymipristone pour le traitement de la depression | |
Rosenbach et al. | Dermatologic therapeutics: thalidomide. A practical guide | |
WO2019097426A1 (en) | Pharmaceutical combination comprising lsz102 and ribociclib | |
WO2017004040A1 (en) | Thromboxane receptor antagonists in aerd/asthma | |
AU2005283829A1 (en) | Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder | |
TW200902028A (en) | Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases | |
WO2008110050A1 (fr) | UTILISATION DE GINSENOSIDE Rg1 ET DE SES MÉTABOLITES GINSENOSIDE Rh1 ET PpT | |
Xiao et al. | KLF11 enhances the effect of liraglutide in high glucoseinduced Schwann cells by regulating endoplasmic reticulum stress and autophagy through inactivation of P38 MAPK |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTHING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC(EPO COMMUNICATIONS=> FORMS 1205A DATED 22.08.2007 AND 01.10.2007) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05818422 Country of ref document: EP Kind code of ref document: A1 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 5818422 Country of ref document: EP |